Rigel Pharmaceuticals, a clinical-stage biotechnology company focused on immunology, oncology and immuno-oncology, has appointed Anne-Marie Duliege as chief medical officer to replace Elliott Grossbard, who is to retire after 14 years of service. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).
Duliege recently served as chief of strategic development and head of immuno-oncology at ChemoCentryx. Previously, she was responsible for providing critical pipeline development results at Affymax. She ultimately held the position of chief medical officer and head of research and clinical development at Affymax, having grown the clinical development organization and successfully managed the development of its first marketed product through international clinical studies, resulting in NDA approval by the FDA. She also held senior positions at Chiron Corporation and Genentech.
“Duliege’s experience overseeing hematology product approvals will be put to immediate use at this crucial stage in our fostamatinib program, and she will play a significant role in the advancement of our entire product pipeline,” stated Raul Rodriguez, CEO of Rigel.
Based in South San Francisco, California, Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.